ALLOGENEIC T CELLS GENETICALLY MODIFIED WITH A RETROVIRAL VECTOR ENCODING FOR A TRUNCATED FORM OF THE HUMAN LOW AFFINITY NERVE GROWTH FACTOR RECEPTOR (DELTALNGFR) AND THE HERPES SIMPLEX I VIRUS THYMIDINE KINASE (HSV-TK MUT2)
drugOn this page
Also known as Zalmoxis
Summary
Allogeneic T Cells Genetically Modified With A Retroviral Vector Encoding For A Truncated Form Of The Human Low Affinity Nerve Growth Factor Receptor (Deltalngfr) And The Herpes Simplex I Virus Thymidine Kinase (Hsv-Tk Mut2) (CHEMBL5315097) is an approved unknown; indicated across 3 conditions including graft versus host disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 3 conditions
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5315097 |
| Name | ALLOGENEIC T CELLS GENETICALLY MODIFIED WITH A RETROVIRAL VECTOR ENCODING FOR A TRUNCATED FORM OF THE HUMAN LOW AFFINITY NERVE GROWTH FACTOR RECEPTOR (DELTALNGFR) AND THE HERPES SIMPLEX I VIRUS THYMIDINE KINASE (HSV-TK MUT2) |
| Type | Unknown |
| Max phase | 4 |
Also known as: Zalmoxis
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| graft versus host disease | 4 | MONDO:0013730 | MONDO:0013730 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: graft versus host disease